SG Americas Securities LLC Decreases Stock Position in Henry Schein, Inc. $HSIC

SG Americas Securities LLC lessened its stake in Henry Schein, Inc. (NASDAQ:HSIC) by 8.0% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 301,784 shares of the company’s stock after selling 26,127 shares during the period. SG Americas Securities LLC owned about 0.25% of Henry Schein worth $20,029,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of HSIC. Artisan Partners Limited Partnership lifted its position in Henry Schein by 0.9% in the second quarter. Artisan Partners Limited Partnership now owns 6,462,204 shares of the company’s stock valued at $472,064,000 after purchasing an additional 55,653 shares during the last quarter. Ameriprise Financial Inc. raised its holdings in Henry Schein by 3,275.2% during the 2nd quarter. Ameriprise Financial Inc. now owns 2,266,858 shares of the company’s stock valued at $165,594,000 after buying an additional 2,199,695 shares during the last quarter. Schroder Investment Management Group raised its holdings in Henry Schein by 149.3% during the 2nd quarter. Schroder Investment Management Group now owns 1,563,899 shares of the company’s stock valued at $114,243,000 after buying an additional 936,471 shares during the last quarter. Swedbank AB boosted its position in Henry Schein by 12.4% during the 3rd quarter. Swedbank AB now owns 1,299,571 shares of the company’s stock valued at $86,253,000 after buying an additional 143,173 shares during the period. Finally, Norges Bank bought a new stake in Henry Schein in the 2nd quarter worth $89,476,000. 96.62% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts have recently commented on the stock. Barclays started coverage on shares of Henry Schein in a research note on Monday, December 8th. They set an “overweight” rating and a $86.00 price objective for the company. Wells Fargo & Company upped their price target on Henry Schein from $70.00 to $76.00 and gave the company an “equal weight” rating in a research report on Wednesday, November 5th. Morgan Stanley increased their price objective on Henry Schein from $55.00 to $58.00 and gave the stock an “underweight” rating in a report on Wednesday, November 5th. Barrington Research set a $79.00 price objective on Henry Schein and gave the stock an “outperform” rating in a research report on Wednesday, November 5th. Finally, Evercore ISI upped their target price on Henry Schein from $83.00 to $90.00 and gave the company an “outperform” rating in a report on Wednesday, November 5th. Five equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Henry Schein has a consensus rating of “Hold” and an average target price of $76.33.

Henry Schein Stock Up 1.1%

HSIC stock opened at $79.00 on Friday. Henry Schein, Inc. has a fifty-two week low of $60.56 and a fifty-two week high of $82.49. The company has a market capitalization of $9.30 billion, a price-to-earnings ratio of 25.00, a price-to-earnings-growth ratio of 2.32 and a beta of 0.88. The business’s 50 day moving average price is $74.27 and its two-hundred day moving average price is $70.37. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.79 and a current ratio of 1.40.

Henry Schein (NASDAQ:HSIC) last released its quarterly earnings results on Tuesday, November 4th. The company reported $1.38 earnings per share for the quarter, beating the consensus estimate of $1.27 by $0.11. The company had revenue of $3.34 billion for the quarter, compared to analyst estimates of $3.28 billion. Henry Schein had a return on equity of 14.76% and a net margin of 3.02%.Henry Schein has set its FY 2025 guidance at 4.880-4.960 EPS. As a group, analysts forecast that Henry Schein, Inc. will post 4.74 earnings per share for the current fiscal year.

Henry Schein Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.